'Yin and Yang' in inflammation: Duality in innate immune cell function and tumorigenesis

Expert Opinion on Biological Therapy

Volumn 8, Issue 10, 2008, Pages 1461-1472

  Khatami, Mahin ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Ageing; Alzheimer's; Angiogenesis; Apoptosis; Atherosclerosis; B cell; Cancer; Cardiovascular disease; Chemokines; Conjunctiva; Cytokines; Dendritic cells; Dual functions; Eosinophils; Hyperplasia; Hypertention; Inflammatory diseases; Innate and adoptive immune cells; Interferons; Interleukins; Leaky mast cells; Lupus; Lymphoid hyperplasia; Macrophages; Mast cells; Natural killers; Neoplasia; Neutrophils; Ocular inflammation; Pleiotropic; Resolution of inflammation; T cell; Tumoricidal; Tumorigenesis; Tumorigenic; Wound healing

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CELECOXIB; COLONY STIMULATING FACTOR 1; CYTOKINE; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MASS CELL STABILIZING AGENT; MATRIX METALLOPROTEINASE INHIBITOR; PROSTAGLANDIN INHIBITOR; PROTEIN KINASE B INHIBITOR; ROFECOXIB; STABILIZING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIOX;

ADAPTIVE IMMUNITY; AGING; ALLERGIC DISEASE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER PREVENTION; CARCINOGENESIS; CELL ACTIVITY; CELL FUNCTION; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INFLAMMATION; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; MAST CELL DEGRANULATION; MOLECULAR DYNAMICS; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR GROWTH; VASCULAR DISEASE; WOUND HEALING;

APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; IMMUNITY, INNATE; INFLAMMATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 54349104915     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.10.1461     Document Type: Article

References (75)

1. Lodoen MB, Lanier LL. Natural killer cells as an initial defense against pathogens. Curr Opin Immunol 2006;18:391-8
2. Valent P, Schernthaner GH, Sperr WR, et al. Variable expression of activation-linked surface antigens on human mast cells in health and disease. Immunol Rev 2001;179:74-81
3. Bonasio R, von Andrian U. Generation, migration and function of circulating dendritic cells. Curr Opin Immunol 2006;18:503-11
4. Drayton, DL, Liao S, Mounzer RH, Ruddle NH. Lymphoid organ development; from ontology to neogenesis. Nat Immunol 2006;7:344-53
5. Kabelitz D, Medzhitov R. Innate immunity-cross-calk with adaptive immunity through pattern recognition receptors and cytokines. Curr Opin Immunol 2006;19:1-3
6. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9
7. Ferratini M, Capone L, Belardelli F. Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Factor Rev 2008;19:93-107
8. Escribano L, Akin C, Castells M, et al. Current opinion in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets 2006;5:61-77
9. Wood JD. Histamine, mast cells, and the enteric nervous system in the irritable bowel syndrome, enteritis and food allergies. Gut 2006;55:445-7
10. Dalgleish AG, O'Bryrne K. Inflammation and cancer: the role of immune response and angiogenesis. Cancer Treat Res 2006;130:1-38
11. Filippo CD, Cuzzocrea S, Rossi F, et al. Oxidative stress as the leading cause of acute myocardial infarction in diabetics. Cardiovasc Drug Rev 2006;24:77-87
12. Ignarro LJ, Napoli C. Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis. Curr Diab Rep 2005;5:17-23
13. Varo N, Libby P, Nuzzo R, et al. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Diab Vasc Dis Res 2005;2:81-7
14. De Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37
15. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45
16. Swann JB, Vesely MD, Silva A, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 2008;105:652-6
17. Wang RF, Miahara Y, Wang HY. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 2008;27:181-9
18. Vakinin-Dembinsky A, Balashov K, Weiner HL. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 2006;176:1768-74
19. Kay AB. The role of eosinophils in the pathogenesis of asthma. Trends Mol Med 2005;11:148-52
20. Khatami M, Donnely JJ, John T, Rockey JH. Vernal conjunctivitis. Model studies in guinea pigs immunized topically with fluoresceinyl ovalbumin. Arch Ophthalmol 1984;102:1683-8
21. Ginaldi L, Martinis MD, Monti D, Franceschi C. Chronic antigenic load and apoptosis in immunosenescence. Trends Immunol 2005;28:79-84
22. Alberti S, Cevenini E, Ostan R, et al. Age-dependent modifications of Type 1 and Type 2 cytokines within virgin and memory CD4+ T cells in humans. Mech Ageing Dev 2006;127:560-6
23. Vaziri H, Benchimol S. Alternative pathways for the extension of cellular life span: inactivation of p53/pRb and expression of telomerase. Oncogene 1999;18:7676-80
24. Gupta S. Molecular steps of cell suicide: an insight into immune senescence. J Clin Immunol 2000;20:229-39
25. LeMaoult J, Manavalan JS, Dyall R, et al. Cellular basis of B cell clonal population in old mice. J Immunol 1999;162:6384-91
26. Zhao C, Li WW, Franklin RJ. Differences in the early inflammatory responses to toxin-induced demyelination are associated with the age-related decline in CNS remyelination. Neurobiol Aging 2006;27:1298-307
27. Karman J, Ling C Sauder M, Fabry Z. Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol 2004;173:2353-61
28. Karni A, Abraham M, Monosonego A, et al. Innate immunity in multiple sclerosis: Myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006;177:4196-202
29. Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol 2006;7:354-9
30. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52
31. Fukata M, Abreu MT. Role of coll-like receptor in gastrointestinal malignancies. Oncogenes 2008;27:234-43
32. Conroy H, Marshall NA, Mills KHG. TLR ligand suppression or enhancement of Treg cell? A double edged sword in immunity to tumours. Oncogenes 2008;27:168-80
33. Wilson NS, Villadangos JA. Lymphoid organ dendritic cells: beyond the Langerhans cells paradigm. Immunol Cell Biol 2004;82:91-8
34. Juliet PA, Hayashi T, Iguchi A, Ignarro LJ. Concomitant production of nitric oxide and superoxide in human macrophages. Biochem Biophys Res Commun 2003;310:367-70
35. Selsing E. Ig class switching: targeting the recombinational mechanism. Curr Opin Immun 2006;18:249-54
36. Caro AA, Cederbaum AJ. Role of cytochrome p450 in phospholipase A2- and arachidonic acid-mediated cytotoxicity. Free Radic Biol Med 2006;40:364-75
37. Ibrahim FBM, Pang SJ, Melendez AJ. Anaphylatoxin signaling in human neutrophils: a key role for sphingosine kinase. J Biol Chem 2004;279:44802-11
38. Peerschke EI, Yin W, Grigg SE, Ghebrehiwer B. Blood platelets activate the classical pathways of human complement. J Thromb Harmost 2006;4:2035-42
39. Yano K, Yamaguchi M, de Mora F, et al. Production of macrophage inflammatory protein-α by human mast cells: increased anti-IgE-dependent secretion after IgE-dependent enhancement of mast cell IgE-binding ability. Lab Invest 1997;77:185-93
40. Monteseirin J, Chacon P, Vega A, et al. Human neutrophils synthesize IL-8 in an IgE-mediated activation. J Leukocyte Biol 2004;76:692-700
41. Nyakern M, Cappellini A, Mantovani I, Marcelli AM. Synergistic induction and apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther 2006;5:1559-70
42. Fischetti F, Tedesco F. Cross-calk between the complement system and endothelial cells in physiologic conditions and vascular diseases. Autoimmunity 2006;39:417-28
43. Perez R, Matabosch X, Llebaria A, et al. Blockade of arachidonic acid incorporation into phospholipids induces apoptosis in U 937 promonocytic cells. J lipid Res 2006;47:484-91
44. Montovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008;371(9614):771-83
45. Snook CF, Jones JA, Hannun YA. Sphingolipid-binding proteins. Biochim Biophys Acta 2006;176:927-46
46. Ledeen RW, Wu G. GMI ganglioside: another nuclear lipid that modulates nuclear calcium: GMI potentiates the nuclear sodium-calcium exchanger. Can J Physiol 2006;84:393-402
47. Hanukoglu I. Antioxidant protective mechanisms against reactive oxygen species (ROS) generated by mitochondrial p450 systems in steroidogenic cells. Drug Metab Rev 2006;38:171-96
48. Berger SA. Signaling pathways influencing SLF and c-kit-mediated survival and proliferation. Immunol Res 2006;35:1-12
49. Ii M, Yamamoto H, Adachi Y, et al. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoprosis, growth, and angiogenesis. Exp Biol Med 2006;23:20-7
50. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006;99:675-91
51. Viappiani S, Sariahmetoglu M, Schulz R. The role of matrix metalloproteinase inhibitors in ischemia-reperfusion injury in the liver. Curr Pharm Des 2006;12:2923-34
52. Murooka TT, Wong MM, Rahbar R, et al. CCL5-CCR5-mediated apoptosis in T cells: Requirement for glycosaminoglycan binding and CCL5 aggregation. J Biol Chem 2006;281:25184-94
53. Khatami M. Developmental phases of inflammation-induced massive lymphoid hyperplasia and extensive changes in epithelium in an experimental model of allergy. Implications for a direct link between inflammation and carcinogenesis. Am J Ther 2005;12:117-28
54. Thompson LJ, Kolumam GA, Thomas S, Murali-Krishna K. Innate inflammatory signals induced by various pathogens differentially dictate the IFN-1 dependence of CD8 T cells for clonal expansion and memory formation. J Immunol 2006;177:1746-54
55. Singh V, Agrewala JN. Regulatory role of pro-Th1 and pro-Th2 cytokines in modulating the activity of Th1 and Th2 cells when B cell and macrophages are used as antigen presenting cells. BMC Immunol 2006;7:17-26
56. Al-Sarireh B, Eremin O. Tumour-associate macrophages (TAMs): disordered function immune suppression and progressive tumour growth. J R Coll Surg Edinb 2000;45:1-16
57. Gurish F, Boyce JA. Mast cells: ontogeny, homing, and recruitment of a unique innate effector cell. J Allerg Clin Immunol 2006;117:1285-91
58. Takanami I, Takeuchi K, Naruke M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 2000;88:2686-92
59. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12
60. Hussein MR. Tumour-associated macrophages and melanoma tumorigenesis: integrating the complexity. Int J Exp Pathol 2006;87:163-76
61. Fricke I, Gabrilovich DI. Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 2006;35:459-83
62. Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 2004;25:235-41
63. Zitvogel L, Apetoh L, Chitinghelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008;8:59-73
64. Jawdat DM, Rowden G, Marshall JN. Mast cells have pivotal role in TNF-independent lymph node hypertrophy and the mobilization of Langerhans cells in response to bacterial peptidoglycan. J Immunol 2006;177:1755-62
65. Ribatti D, Ennas MD, Vacca A, et al. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 2003;33:420-5
66. Quintas-Cardama A, Aribi A, Cortes J, et al. Novel approaches in the treatment of systemic mastocytosis. Cancer 2006;107:1429-39
67. Khatami M. Standardizing cancer biomarkerscriteria:data elements as a foundation for a database. Inflammatory mediator/M-CSF as model marker. Cell Biochem Biophys 2007;47:187-98
68. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999;13:1382-97
69. Tomita M, Matsuzaki Y, Onits uka T. Correlation between mast cells and survival rates in patients with pulmonary adenocarcinoma. Lung Cancer 1999;26:103-8
70. Mroczko B, Szmikowski M, Wereszcynka-Siemiatkowska U, Jurkowski M. Stem cell factor and macrophage-colony stimulating factor in patients with pancreatic cancer. Clin Chem Lab Med 2004;42:256-60
71. Khatami M, Donnelly JJ, Rockey JH. Induction and down-regulation of conjunctival type-1 hypersensitivity reactions in guinea pigs sensitized topically with fluoresceinyl ovalbumin. Ophthal Res 1985;17:139-47
72. Haldar JP, Khatami M, Donnelly JJ, Rockey JH. Experimental allergic conjunctivitis: production of different isotypes of antibody by conjunctival-associated lymphoid tissue in culture. Regional Immunol 1988;1:92-9
73. Khatami M, Donnelly JJ, Haldar JP, Rockey JH. Massive follicular lymphoid hyperplasia in experimental chronic recurrent allergic conjunctivitis. Arch Ophthalmol 1989;107:433-8
74. Hellebold L, Khatami, M, Wei Z-G, Rockey JH. Histamine and prostacyclin: primary and secondary release in allergic conjunctivitis. Invest Ophthalmol Vis Sci 1991;31:2281-9
75. Khatami M. Cyclooxygenase inhibitor Ketorolac or mast cell stabilizers: immunological challenges in cancer therapy. Clin Cancer Res 2005;11:1350-2